Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05690386 · ClinicalTrials.gov registry record · Phase 2
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
A Phase 2 study of Turner Syndrome, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 19
- Study locations
NCT05690386: Active Phase 2 study of Turner Syndrome, sponsored by Ascendis Pharma Endocrinology Division A/S.
NCT05690386 is a Phase 2 study of Turner Syndrome that is active but no longer recruiting, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 48 participants, below the 516-participant average among 14 other Turner Syndrome trials with a reported enrollment target (91% lower). The trial reports 19 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05690386, a Phase 2 study of Turner Syndrome, is active but no longer recruiting, sponsored by Ascendis Pharma Endocrinology Division A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 19
- Study locations
Study Summary
A 104 week dose finding open label trial followed by an optional 78 week open label extension of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 individuals (12 individuals per arm) will be randomized to receive one of three doses of lonapegsomatropin or a daily injection of somatropin. This is a trial that will be conducted in the United States.
Primary Outcome
Calculated based on the difference between the AHV at 6 months and baseline
Conditions Studied
Interventions
- DRUG Somatropin
- BIOLOGICAL Lonapegsomatropin
Study Locations (19)
California
- Ascendis Pharma Investigational Site - Palo Alto
- Ascendis Pharma Investigational Site - San Diego
Florida
- Ascendis Pharma Investigational Site - Orlando
- Ascendis Pharma Investigational Site - St. Petersburg
Texas
- Ascendis Pharma Investigational Site - El Paso
- Ascendis Pharma Investigational Site - Fort Worth
Colorado
- Ascendis Pharma Investigational Site - Aurora
Georgia
- Ascendis Pharma Investigational Site - Atlanta
Idaho
- Ascendis Pharma Investigational Site - Idaho Falls
Illinois
- Ascendis Pharma Investigational Site - Chicago
Massachusetts
- Ascendis Pharma Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What the registry record for NCT05690386 still lists
NCT05690386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 516-participant average among 14 other Turner Syndrome trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Turner Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Somatropin is the first listed.
NCT05690386 lists 19 locations in 16 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT05690386 about?
NCT05690386 is a clinical study titled "A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome". A 104 week dose finding open label trial followed by an optional 78 week open label extension of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 individuals (12 individ...
What is the current status of trial NCT05690386?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2023-02-15. Estimated completion is 2027-12.
What conditions does trial NCT05690386 study?
This clinical trial studies the following conditions: Turner Syndrome.
What interventions are being tested in trial NCT05690386?
The interventions under investigation include: Somatropin (DRUG), Lonapegsomatropin (BIOLOGICAL).
Who is sponsoring clinical trial NCT05690386?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05690386 being conducted?
This trial has 19 study locations across California, Colorado, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Turner Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05690386's enrollment target sits among peer trials
48 11th of 14 higher than 4 of 14 other Turner Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Turner Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vosoritide for Short Stature in Turner Syndrome
RECRUITING · Phase 2
-
A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
RECRUITING · Phase 2
-
Natural History of Noncirrhotic Portal Hypertension
RECRUITING
-
UTHealth Turner Syndrome Research Registry
RECRUITING
-
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
RECRUITING · Phase 4
-
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI